Press Releases MediWound Ltd.

Equities

MDWD

IL0011316309

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
18.24 ^USD	+3.28%		+15.66%	+79.35%

Mar. 21	MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026	CI
Mar. 21	Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	Apr. 25	GL
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences	Apr. 25	AQ
MediWound: Q4 Earnings Snapshot	Mar. 21	AQ
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	Mar. 21	GL
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	Mar. 14	GL
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results	Mar. 14	AQ
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study	Feb. 12	GL
MediWound to Participate in Two Upcoming Investor Conferences	Feb. 05	GL
MediWound to Participate in Two Upcoming Investor Conferences	Feb. 05	AQ
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	Jan. 09	GL
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns	Jan. 09	AQ
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army	Dec. 29	AQ
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army	Dec. 28	GL
MediWound Announces Peer-Reviewed Publication of EscharEx Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads	Dec. 22	AQ
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads	Dec. 21	GL
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	Dec. 20	AQ
MediWound : Presentation – December 2023	Dec. 18	PU
MediWound: Q3 Earnings Snapshot	Nov. 21	AQ
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update	Nov. 21	GL
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer	Nov. 21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MediWound Ltd.

Equities

MDWD

IL0011316309

Press Releases

Filters